TABLE 2.
Virus | Coreceptora | HR1b | IC50 (μg/ml) | Mean IC50c (μg/ml) | SD | Changed |
---|---|---|---|---|---|---|
NL-FLV3 | R5 | DIV | 0.443 | 0.421 | 0.02 | 0.0 |
NFN-SM | R5 | DIV | 0.397 | |||
NFN-SP | R5 | DIV | 0.423 | |||
NL4.3 | X4 | DIV | 0.120 | 0.125 | 0.01 | −0.5 |
NL(Stu)Xba | X4 | DIV | 0.130 | |||
MX-FLV3 | R5 | GIV | 0.056 | 0.032 | 0.01 | −1.1 |
NFN-SX | R5 | GIV | 0.047 | |||
NLHX SF2 V3 | R5 | GIV | 0.025 | |||
NLHX ADA V3B | R5 | GIV | 0.019 | |||
NLHX ADA V3 | R5 | GIV | 0.024 | |||
NLHX SF162 V3 | R5 | GIV | 0.032 | |||
NFN-MX | X4 | GIV | 0.008 | 0.007 | 0.00 | −1.8 |
NLHX | X4 | GIV | 0.005 |
Coreceptor specificity of each chimeric virus.
Amino acids 36 to 38 in the gp41 N-terminal heptad repeat that comprise a critical T-20 target site.
Calculated for chimeric viruses grouped by coreceptor specificity and T-20 target site.
Independent effects of coreceptor specificity and T-20 target site represented on a log10 scale using group mean IC50s.